In a phase III trial, it was used with docetaxel to treat advanced NSCLC and significantly improved PFS.410 Apatinib, another VEGFR-2 inhibitor, has shown a 76.7% disease control rate in treating NSCLC patients who did not respond to initial or follow-up treatments.411 Fruquintinib, a newer small molecule inhibitor, has also demonstrated promising results, with a 71% increase in progression-free survival compared to a control group in advanced non-squamous NSCLC treatment.412. The gene discussed is KDR; the disease is non-small cell lung carcinoma.